ONCOLOGY Nurse Edition Vol 23 No 11

There has been a growing recognition in recent years that young adults with cancer are a distinct demographic group with unique needs, issues, and challenges related to their age and developmental stage of life.

Ms. Hydzik's article on intraperitoneal chemotherapy (IPC) for the treatment of ovarian cancer provides the rationale for IPC, presents the supporting evidence, and describes nursing management of these patients through the Memorial Sloan-Kettering Cancer Center experience.

In July 2009, the US Food and Drug Administration (FDA) granted approval for use of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab (Avastin) in combination with interferon alfa for treatment of patients with metastatic renal cell carcinoma (RCC).

Ovarian cancer is the most deadly gynecologic malignancy. In the US alone, an estimated 21,500 new cases will be diagnosed in 2009, and an estimated 14,600 women will die from this disease.

For young adult survivors, coming to terms with a life-threatening illness is a unique dilemma.

The US Food and Drug Administration's Office of Oncology Drug Products has announced class labeling changes to product labels for the anti-EGFR

As oncology nurses, we increasingly encounter issues related to integrative medicine in our community practices, clinics, and hospitals.

Vitamin D-the so-called “sunshine vitamin”-is a fat-soluble substance and is classified more as a pro-hormone or steroid by some

Hypothyroidism is a common and potentially serious endocrine disorder in the general population.

October marks National Breast Cancer Awareness month, now in its 25th year, a time to contemplate important advances and milestones as well as future research needs.

In the US, breast cancer is the most common invasive cancer in women, with more than 200,000 diagnosed with the disease each year.